Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd.

Evogene Trading Down 3.0 %

Shares of Evogene stock opened at $1.62 on Tuesday. The firm’s 50 day moving average is $2.34 and its 200 day moving average is $4.37. The firm has a market capitalization of $8.69 million, a PE ratio of -0.37 and a beta of 1.43. Evogene has a 1 year low of $1.44 and a 1 year high of $10.40.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.